CRYAB and relapsing-remitting multiple sclerosis: In this 48-week randomized, placebo-controlled, double-blind phase IIa trial, three bimonthly intravenous injections of 7.5, 12.5, or 17.5 mg HspB5 were determined to be safe and well-tolerated in patients with relapsing-remitting MS (RRMS).